April 2024

Sun Pharmaceutical Industries Limited is taking this opportunity to balance employment and the medications to the world. We arc hereby inviting candidates who are interested to join India's No. I company in Pharmaceutical sector.

Manufacturing / Packing (Parenteral)
Post : Technician to Senior Executive
Experience : 2-8 Years
Qualification : ITI/ Diploma/B.Pharma / M.Pharma

We help biopharmaceutical, emerging biotech and medical device companies develop products, get them to the market, and grow their impact through the life cycle in a more effective, efficient, and modern way. We bring together healthcare domain expertise, fit-for-purpose technology, and an agile operating model to provide a diverse range of solutions. These aim to deliver, amongst other outcomes, a personalized, scalable and omnichannel experience for patients and physicians.

Indoco Remedies Ltd., is a fully integrated, research-oriented pharma company engaged in the manufacturing and marketing of Formulations and Active Pharmaceutical Ingredients (APIs). We have seven decades of presence in the Indian Pharma market and a strong foothold in the international market across 55 countries. Indoco, a USD 166 million company, employs around 6000 personnel, including over 300 skilled scientists.

WALK-IN-INTERVIEW For our tablet manufacturing facility in Goa

Emcure is fast-growing Indian pharmaceutical company engaged in developing, manufacturing, and marketing a broad range of pharmaceutical products globally. With a presence in over 70 countries, Emcure's goal is to constantly innovate and deliver affordable & high-quality healthcare solutions to people.

Aarti Pharmalabs Limited engages in the development of Active Pharmaceutical Ingredients (API) and New Chemical Entities (NCE), API intermediates, Regulatory Starting Materials (RSM), Basic Starting Materials, Key Building Blocks, and Xanthine Derivatives for use in clinical testing and commercial production. In addition to process R&D, we provide stability studies, scale-up and process optimisation, process validations, and commercial manufacturing.

GSK is a global biopharma company with a special purpose – to unite science, technology and talent to get ahead of disease together – so we can positively impact the health of billions of people and deliver stronger, more sustainable shareholder returns – as an organisation where people can thrive. Getting ahead means preventing disease as well as treating it, and we aim to impact the health of 2.5 billion people around the world in the next 10 years. 

Post : Quality Control Lead

Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals, and branded generic medicines. Our 109,000 colleagues serve people in more than 160 countries.

Post : Therapy Business manager - Women's Health- Mumbai (Thane)

In the largest study to date on the subject, researchers found no evidence to support a causal link between acetaminophen use during pregnancy and increased risk of autism, ADHD and intellectual disability in children. The findings, using data from a nationwide cohort of over 2.4 million children born in Sweden, including siblings not exposed to the drug before birth, were published today in the Journal of the American Medical Association (JAMA) from researchers at Drexel’s Dornsife School of Public Health and Karolinska Institutet of Sweden.

Almost 1 in 5 adults with congenital heart disease living in Israel had or developed an abnormal heart rhythm/arrhythmia during a five-year study, according to new research published in the Journal of the American Heart Association, an open access, peer-reviewed journal of the American Heart Association.

Novartis today announced data from the ALITHIOS open-label extension study showing sustained efficacy of first-line, continuous Kesimpta® (ofatumumab) treatment for up to six years in recently diagnosed – defined as starting treatment within three years of initial diagnosis – treatment-naïve people living with relapsing multiple sclerosis (RMS).